MetaVia Inc
metaviatx.comWhat Do They Do?
Develops drug candidates for people with obesity and metabolic dysfunction-associated steatohepatitis (MASH), with a candidate also aimed at type two diabetes.
10-K for FY2025, filed Mar 26, 2026OverviewView ↗
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We…View ↗
Vanoglipel (DA-1241) is a novel GPR119 (“GPR119”) agonist with development optionality as a standalone or combination therapy for both MASH…View ↗
DA-1726 is a novel oxyntomodulin (“OXM”) analog functioning as a GLP-1 receptor (“GLP1R”) and glucagon receptor (“GCGR”) dual agonist for…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$5.3MView ↗
- ▲ +33% (Loss)
- vs −$4M in Q2 FY2025
Obesity program focus
The older report described the obesity candidate as being developed for both liver disease and obesity; the latest report presents it as an obesity program, while the other candidate is focused on liver disease and type two diabetes.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 26, 2026DA-1726 is a novel oxyntomodulin (“OXM”) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity that is to…View ↗
Legacy programs
The older report said the company would consider licensing and acquisition opportunities for legacy programs; the latest says it will not advance those programs and is considering out-licensing or divestiture.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 26, 2026Our Board of Directors has determined to focus our financial resources and management attention on development of DA-1241 for NASH and T2D…View ↗
While we focus our financial resources and management’s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four…View ↗
Who Do They Compete With?
Competes with Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Akero Therapeutics, 89 Bio, Inventiva, Boston Pharmaceuticals, Roche, Intercept Pharmaceuticals, AstraZeneca, Altimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Durect, Galectin Therapeutics, Galmed Pharmaceuticals, Immuron, Ionis Pharmaceuticals, Islet Sciences, and MediciNova
10-K for FY2025, filed Mar 26, 2026There is only one approved treatment of MASH, Madrigal Pharmaceuticals’ thyroid hormone receptor beta agonist. However, various…View ↗
Loading...
